Scarcell Therapeutics Announces EMA Recognition of Its Original Tissue Therapy, Developed from Heterologous Gingival Fibroblasts[1], as a Tissue Engineered Treatment

Date: July 7, 2022

The Committee of the European Medicines Agency (EMA), which evaluates the quality, safety and efficacy of advanced therapy medicinal products, has just concluded that the tissue therapy developed by Scarcell Therapeutics has all the qualities required to be included in the class of treatments from tissue engineering.

About tissue engineering treatments:
They refer to products which contain or consist of modified cells or tissues which are administered to humans for the purpose of regenerating, repairing, or replacing human tissue.
"This recognition by the EMA is an important step for Scarcell Therapeutics because it validates the tissue repair potential of our original therapeutic solution, developed from heterologous gingival fibroblasts, cells from the human gums," said Christophe Hubert, CEO of Scarcell Therapeutics.

About Scarcell Therapeutics
Scarcell Therapeutics is a biotechnology company founded by Prof. Antoine Lafont, PU-PH at the Georges Pompidou European Hospital in Paris, which is developing the first and only tissue therapy based on heterologous gingival fibroblasts[1].

Gingival fibroblasts have unique properties
Gingival fibroblasts possess unique healing and anti-inflammatory properties and are able to generate in situ a matrix specific to the injured tissue, thus allowing an unparalleled repair, consistent with the original tissues.
Prof. Lafont explains that "This new tissue repair strategy is based on the discovery of specific properties of the gum which, compared to other tissues, has a perfect repair capacity, without scarring or fibrosis. These properties are explained by the presence in the gums of cells specialized in tissue repair: gingival fibroblasts. »

Scarcell Therapeutics' technology aims to transpose the unique characteristics of these gum cells to other tissues using a unique production process that gives it multiplied production capacities without alteration and at an unprecedented cost today. The gingival fibroblasts used by Scarcell Therapeutics are not modified prior

[1] The donor is separate from the recipient

to administration unlike cell therapies in general (mesenchymal stem cells, embryonic stem cells, iPS and CAR-T cells), clearly reducing the biological risk.

Pre-clinical studies with very promising results

The Scientific Director, Dr. Mathieu Castéla specifies that "pre-clinical studies carried out in animal models with gingival fibroblasts have demonstrated precise repair, very close to healthy tissue, in different lesions, a powerful anti-inflammatory action and a prolonged therapeutic duration of action thanks to better survival."

Gingival fibroblasts can produce their own matrix in situ, unlike other tissue engineering products using synthetic matrices. These characteristics allow gingival fibroblasts to repair and integrate with damaged tissues without inducing an immune response.

Contact: christophe.hubert@scarcell.com